The first patient has been dosed in a small clinical trial in Australia that’s testing CTx1000, Celosia Therapeutics’ experimental gene therapy, in people with amyotrophic lateral sclerosis (ALS). The one-time treatment is designed to reduce toxic buildups of the TDP-43 protein, which are believed to contribute to nerve cell…
News
ACI-19626, an experimental imaging agent developed by AC Immune, may safely detect abnormal clumps of the protein TDP-43 in the brain, a hallmark of amyotrophic lateral sclerosis (ALS) and other neurological conditions. That’s according to early data from a Phase 1 clinical trial (NCT06891716) evaluating the safety and…
Early treatment with AL-S Pharma‘s infusion therapy AP-101 significantly extended survival and delayed the need for respiratory support in people with amyotrophic lateral sclerosis (ALS), compared with a six-month delay in starting therapy, new trial data show. The therapy candidate is being developed to target and clear…
The ALS Network and ALS United are inviting U.S. researchers to submit proposals for a new round of funding aimed at accelerating progress toward new treatments for amyotrophic lateral sclerosis (ALS). The funding is part of the expanding ALS Research Innovation Initiative. It’s intended to support “bold” and …
Several commonly used medications may be repurposed to extend survival in people with amyotrophic lateral sclerosis (ALS), according to an analysis of the electronic medical records of more than 11,000 U.S. veterans. Researchers found that certain classes of medications were associated with improved survival in ALS, including statins, which…
An analysis of how polarized light interacts with clumps of proteins in the eyes may help differentiate amyotrophic lateral sclerosis (ALS) from Alzheimer’s disease and related conditions, a new study shows. In experiments using post-mortem retinal samples — a light-sensitive layer at the back of the eye — researchers…
A Phase 2 clinical trial showed that early treatment with the experimental oral therapy PrimeC slowed functional decline and reduced the risk of death or ALS complications for people with amyotrophic lateral sclerosis (ALS) compared with a six-month delay in treatment. Top-line results from the main Phase 2…
A brain implant to detect attempted finger movements can enable people paralyzed by conditions such as amyotrophic lateral sclerosis (ALS) to type on a computer, a study showed. The findings build on a rapidly growing field of research into so-called implantable brain-computer interfaces (iBCIs), in which electrodes are implanted…
Acurastem has received a research grant from Target ALS to develop potential therapies for amyotrophic lateral sclerosis (ALS) that target SYF2, a protein involved in regulating TDP-43 function. Abnormalities in the TDP-43 protein are a hallmark of ALS and are believed to play a central role in…
Amydis has received a $2.5 million grant from the National Institutes of Health (NIH) to develop a simple eye test that could help detect toxic deposits of the TDP-43 protein — a hallmark of amyotrophic lateral sclerosis (ALS) and several other neurodegenerative diseases. With the funding from the…
Recent Posts
- Trial testing new ALS gene therapy starts dosing patients in Australia
- In life with ALS, we find moments of ‘genius’ to keep our minds active
- Brain imaging agent shows promise for detecting toxic ALS protein
- I reframed my life with ALS by becoming a calmer duck
- New ALS treatment improves survival, leads to function gains in trial